Attached files
file | filename |
---|---|
EX-32.1 - EX-32.1 - XERIS PHARMACEUTICALS INC | a202010-kexhibit321.htm |
EX-31.2 - EX-31.2 - XERIS PHARMACEUTICALS INC | a202010-kexhibit312.htm |
EX-31.1 - EX-31.1 - XERIS PHARMACEUTICALS INC | a202010-kexhibit311.htm |
EX-23.1 - EX-23.1 - XERIS PHARMACEUTICALS INC | a202010-kexhibit231.htm |
EX-10.36 - EX-10.36 - XERIS PHARMACEUTICALS INC | a202010-kexhibit1036.htm |
EX-10.34 - EX-10.34 - XERIS PHARMACEUTICALS INC | a202010-kexhibit1034.htm |
10-K - 10-K - XERIS PHARMACEUTICALS INC | xers-20201231.htm |
Exhibit 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report of Xeris Pharmaceuticals, Inc. (the “Company”) on Form 10-K for the year ended December 31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Barry M. Deutsch, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, to the best of my knowledge, that:
1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2. The information contained in the Report fairly presents, in all material aspects, the financial condition and results of operations of the Company.
Date: March 9, 2021
By: | /s/ Barry M. Deutsch | ||||
Barry M. Deutsch | |||||
Chief Financial Officer | |||||
(Principal Financial Officer) |